

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- The investigational agent larotrectinib (LOXO-101) demonstrated response rates higher than 70% for adult and pediatric patients with tumors harboring _____.**
 - MET exon 14 skipping mutations
 - ALK rearrangements
 - NTRK rearrangements**
- Data presented by Sabari and colleagues at ASCO 2017 evaluating the use of immune checkpoint inhibitors for patients with MET exon 14-altered NSCLC found that rates of response to immunotherapy were low overall and lower than those reported with targeted therapy.**
 - True**
 - False
- Pembrolizumab is FDA approved as first-line therapy for metastatic nonsquamous NSCLC in which of the following applications?**
 - As a single agent for patients whose tumors have high PD-L1 TPS and no EGFR or ALK genomic tumor aberrations
 - In combination with pemetrexed and carboplatin
 - Both a and b**
 - Neither a nor b
- Crizotinib is FDA approved for patients with _____ metastatic NSCLC.**
 - ALK-positive
 - MET exon 14-rearranged
 - ROS1-positive
 - All of the above
 - Both a and b
 - Both a and c**
- Which of the following categories reflects the mechanism of action of rovalpituzumab tesirine?**
 - ALK inhibitor
 - Antibody-drug conjugate**
 - Anti-PD-1/PD-L1 antibody
 - EGFR tyrosine kinase inhibitor
- Which of the following ALK inhibitors penetrates the central nervous system (CNS) well and thus exhibits significant activity in patients with NSCLC and CNS metastases?**
 - Alectinib**
 - Crizotinib
 - Both a and b
- Initial results of the Phase III ADJUVANT trial presented at ASCO 2017 demonstrated that adjuvant gefitinib significantly prolonged _____ in comparison to vinorelbine/cisplatin for patients with resected Stage II to IIIA NSCLC with EGFR-activating mutations.**
 - Disease-free survival**
 - Overall survival
 - Both a and b
 - Neither a nor b
- Osimertinib is FDA approved for the treatment of EGFR T790M mutation-positive NSCLC after disease progression on or after another EGFR-blocking therapy.**
 - True**
 - False
- Lorlatinib is an investigational agent in the treatment of NSCLC and a potent inhibitor of _____.**
 - PD-1
 - EGFR
 - ALK**
- Osimertinib _____ marked activity in patients with brain metastases from T790M-positive advanced NSCLC.**
 - Does not exhibit
 - Exhibits**